Clinical Chemistry and Laboratory Medicine

QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening

Retrieved on: 
Thursday, June 15, 2023

The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).

Key Points: 
  • The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).
  • The meta-analysis on QuantiFERON testing was conducted by Universitas Padjadjaran, Indonesia, and published in Clinical Chemistry and Laboratory Medicine (CCLM) [1] .
  • QuantiFERON-TB Gold Plus is the world’s leading IGRA blood test, with millions of tests performed annually.
  • [1] Darmawan, Guntur et al: "Comparison of interferon-gamma production between TB1 and TB2 tubes of QuantiFERON-TB Gold Plus: a meta-analysis" Clinical Chemistry and Laboratory Medicine (CCLM), 2023. https://doi.org/10.1515/cclm-2023-0293

EQS-News: Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

Retrieved on: 
Sunday, November 27, 2022

Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.

Key Points: 
  • Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, November 15, 2022 - Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) today announced they have entered into a non-exclusive royalty-bearing license agreement.
  • The critical state is currently diagnosed by standard-of-care biomarkers when 50% of the kidney function is already lost (1).
  • PenKid addresses these pitfalls, offering an earlier and more precise determination of kidney function in acute and critical care settings (2).
  • Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study.

Fujirebio Diagnostics Lumipulse® G β-Amyloid Ratio (1-42/1-40) In Vitro Diagnostic Test Receives Marketing Authorization for the Assessment of Alzheimer’s Disease

Retrieved on: 
Thursday, May 5, 2022

The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimers disease and other causes of cognitive decline.

Key Points: 
  • The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimers disease and other causes of cognitive decline.
  • Alzheimers disease afflicts more than five million Americans, a number that is expected to triple to almost 14 million by 2050.
  • The Lumipulse G -Amyloid Ratio (1-42/1-40) test is an accurate, minimally invasive, accessible measure of -Amyloid that can detect the formation of amyloid plaques early in the disease.
  • The Lumipulse G -Amyloid Ratio (1-42/1-40) test is not intended as a screening or standalone assay to diagnose AD.

DGAP-News: Proenkephalin (penKid) sheds light on the diagnostic blind spots in assessing acute kidney injury in children

Retrieved on: 
Tuesday, March 15, 2022

For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.

Key Points: 
  • For children burdened with life-threatening acute kidney injury (AKI) there are no reliable diagnostics to assist the management of pediatric AKI.
  • AKI is mostly diagnosed too late for successful intervention which leads to steep mortality rates and chronic kidney disease (1,2).
  • Bennett MR, Nehus E, Haffner C, Ma Q, Devarajan P. Pediatric reference ranges for acute kidney injury biomarkers.
  • Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock.

Veravas Announces Appointments of Chief Scientific Officer and Chief Clinical Officer

Retrieved on: 
Wednesday, June 19, 2019

Veravas, Inc. , an emerging diagnostic company, appointed Joshua Soldo as the chief scientific officer and Carmen Wiley, Ph.D., as chief clinical officer.

Key Points: 
  • Veravas, Inc. , an emerging diagnostic company, appointed Joshua Soldo as the chief scientific officer and Carmen Wiley, Ph.D., as chief clinical officer.
  • Additional roles include corporate director, scientific affairs at DiaSorin and senior development scientist, research and development at Beckman Coulter.
  • Dr. Wiley is a highly-recognized clinical leader in chemistry and laboratory medicine who brings more than 18 years of experience in clinical chemistry and laboratory medicine.
  • Prior to Veravas, she was a regional manager of scientific affairs at Roche Diagnostics.

Ortho Clinical Diagnostics to Present Research on Advances in Cardiac Testing, Diagnostics Technology at EuroMedLab 2019

Retrieved on: 
Thursday, May 16, 2019

RARITAN, N.J., and BARCELONA, Spain, May 16, 2019 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, will sponsor an educational workshop on high-sensitivity troponin assays and present five scientific posters at EuroMedLab 2019.

Key Points: 
  • RARITAN, N.J., and BARCELONA, Spain, May 16, 2019 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, will sponsor an educational workshop on high-sensitivity troponin assays and present five scientific posters at EuroMedLab 2019.
  • EuroMedLab 2019 is the 23rdIFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which will take place from May 19-23 at the CCIB - Centre Convencions Internacional in Barcelona.
  • "Ortho is committed to staying ahead of the rapidly evolving clinical lab environment," said Joan Martin, executive vice president and head of Ortho's EMEA region.
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities.

Siemens Healthineers Exhibits Solutions That Drive Outcomes That Matter to Healthcare Providers and Patients

Retrieved on: 
Thursday, May 16, 2019

There are more than 7.5 billion people on Earth1and each one is deserving of accurate diagnostic test results.

Key Points: 
  • There are more than 7.5 billion people on Earth1and each one is deserving of accurate diagnostic test results.
  • Each healthcare institution faces unique challenges to deliver results quickly and efficiently, which is why Siemens Healthineers is focusing clinical chemistry and laboratory medicine professionals attention on its Outcomes that Matter exhibit (Booth #51) at the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine.
  • Siemens Healthineers will showcase in Booth #51 new innovations for laboratory, point-of-care and molecular testing.
  • Attendees can see firsthand the newest innovation in blood gas for point-of-care testing, which will be unveiled at the show.